Quick Answer
Eton Pharmaceuticals, Inc. reported Revenue (ASC 606) of $79.95 million for fiscal year 2025.
Eton Pharmaceuticals, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $79.95M | +104.9% |
| 2024 | $39.01M | +23.3% |
| 2023 | $31.64M | +48.9% |
| 2022 | $21.25M | -2.7% |
| 2021 | $21.83M | +55879.5% |
| 2020 | $39.0K | -95.9% |
| 2019 | $959.0K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.46M | +117.5% | +18.7% |
| June 30, 2025 | $18.93M | +108.6% | +9.5% |
| March 31, 2025 | $17.28M | +116.9% | +67.4% |
| September 30, 2024 | $10.32M | +46.9% | +13.8% |
| June 30, 2024 | $9.07M | -24.4% | +13.9% |
| March 31, 2024 | $7.97M | +50.2% | +13.3% |
| September 30, 2023 | $7.03M | +118.3% | -41.4% |
| June 30, 2023 | $12.00M | +63.0% | +126.2% |
- Eton Pharmaceuticals, Inc. showed an increase of +104.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2025 period, Eton Pharmaceuticals, Inc.’s revenue (asc 606) has grown by 8236.8% (from $959.0 thousand to $79.95 million).
- The most recent figure is from Eton Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: